滑膜活检在非炎症性和持续性炎症难治性类风湿关节炎中的临床应用
该前瞻性观察队列研究在两家学术风湿病中心纳入93例已确诊且疾病活动的类风湿关节炎患者,行超声引导下滑膜活检。结果显示,非炎症性难治性类风湿关节炎以少免疫/纤维样滑膜病理为主(47.6%),持续性炎症难治性类风湿关节炎则表现为淋巴-髓系和弥漫-髓系病理型并伴更高炎症标志物;非炎症性难治性类风湿关节炎患者疼痛更重、阿片类药物使用更多且健康相关生活质量更差。
要点
- 难治性类风湿关节炎可分为持续性炎症型和非炎症型两种不同滑膜与临床表型
- 非炎症性难治性类风湿关节炎以少免疫/纤维样滑膜病理为主,占47.6%
- 非炎症性难治性类风湿关节炎患者疼痛更重、阿片类药物使用更多且生活质量更差
核心结论
- 研究显示难治性类风湿关节炎存在不同的滑膜与临床表型,持续性炎症难治性类风湿关节炎似由活动性滑膜炎症和免疫细胞浸润驱动,非炎症性难治性类风湿关节炎则以少免疫/纤维样组织学为主并伴有显著非炎症性因素导致疾病负担。
研究设计与样本
- 前瞻性观察队列研究,在两家学术风湿病中心纳入93例已确诊且疾病活动的类风湿关节炎成人患者(临床疾病活动指数>10),行超声引导下滑膜组织活检。
- 依据医师总体评估(>2/10)和C反应蛋白(>5 mg/L)阈值将生物制剂和靶向合成改善病情抗风湿药应答不佳者分为持续性炎症难治性类风湿关节炎或非炎症性难治性类风湿关节炎,未使用过生物制剂和靶向合成改善病情抗风湿药者归为非难治性类风湿关节炎。
- 组织病理学评估包括Krenn滑膜炎评分和免疫组化病理型评估(淋巴-髓系、弥漫-髓系、少免疫/纤维样)。
主要发现
- 93例活检患者中,持续性炎症难治性类风湿关节炎43例、非炎症性难治性类风湿关节炎21例、非难治性类风湿关节炎29例。
- 非炎症性难治性类风湿关节炎Krenn滑膜炎评分较低(P = .012),淋巴聚集较少(P < .001),且以少免疫/纤维样病理型为主(21/43,47.6%)。
- 持续性炎症难治性类风湿关节炎更多表现为淋巴-髓系和弥漫-髓系病理型,并伴有更高的炎症标志物和超声能量多普勒评分。
- 非炎症性难治性类风湿关节炎发生少免疫纤维样滑膜炎的相对风险为1.6(95% CI 1.2至2.9,P = .006),较持续性炎症难治性类风湿关节炎风险有统计学显著增加。
- 尽管总体疾病活动度评分相似,非炎症性难治性类风湿关节炎患者较持续性炎症难治性类风湿关节炎疼痛更重(P = .005)、阿片类药物使用更多(P = .015),且健康相关生活质量较持续性炎症难治性类风湿关节炎或非难治性类风湿关节炎更差。
关键数值与推荐
- 非炎症性难治性类风湿关节炎发生少免疫纤维样滑膜炎的相对风险为1.6(95% CI 1.2至2.9,P = .006)。
- 非炎症性难治性类风湿关节炎中少免疫/纤维样病理型为21/43(47.6%)。
- 持续性炎症难治性类风湿关节炎43例、非炎症性难治性类风湿关节炎21例、非难治性类风湿关节炎29例。
- 非炎症性难治性类风湿关节炎Krenn滑膜炎评分较低(P = .012),淋巴聚集较少(P < .001)。
- 非炎症性难治性类风湿关节炎疼痛评分(P = .005)和阿片类药物使用(P = .015)均高于持续性炎症难治性类风湿关节炎。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We aimed to characterise the synovial pathology of refractory rheumatoid arthritis (RA) by comparing two hypothesised clinical phenotypes-persistent inflammatory refractory RA (PIRRA) and noninflammatory refractory RA (NIRRA)-against nonrefractory RA (NORRA). METHODS: We conducted a prospective, observational cohort study at two academic rheumatology centres. Adult patients with established RA and active disease (Clinical Disease Activity Index >10) underwent ultrasound-guided synovial tissue biopsies in accordance with European Alliance of Associations for Rheumatology-Outcome Measures in Rheumatology guidelines. Based on the Physician Global Assessment (>2/10) and C-reactive protein (>5 mg/L) thresholds, biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs)-inadequate responders patients were classified as PIRRA or NIRRA, whereas b/tsDMARD-naïve were designated NORRA. Histopathological assessments included the Krenn Synovitis Score (KSS) and immunohistochemistry pathotype evaluation (lympho-myeloid, diffuse-myeloid, pauci-immune/fibroid). RESULTS: Of the 93 biopsied patients, 43 were PIRRA, 21 NIRRA, and 29 NORRA. NIRRA had lower KSS (P = .012), lymphoid aggregates (P < .001) and predominantly pauci-immune/fibroid pathotype (n = 21/43, 47.6%), whereas PIRRA displayed more lympho- and diffuse-myeloid pathotypes, coupled with higher inflammatory markers and ultrasound-power Doppler scores. The relative risk of having pauci-immune fibroid synovitis for NIRRA was 1.6 (95% CI 1.2 to 2.9, P = .006), indicating a statistically significant increase in risk compared to PIRRA. Despite having similar overall disease activity scores, NIRRA patients reported significantly greater pain (P = .005) and higher opioid use (P = .015) than PIRRA, and worse health-related quality of life than PIRRA or NORRA, underscoring noninflammatory mechanisms. CONCLUSIONS: Our findings demonstrate distinct synovial and clinical phenotypes in refractory RA. Although PIRRA appears driven by active synovial inflammation and immune cell infiltration, NIRRA involves predominantly pauci-immune/fibroid histology with significant noninflammatory contributors to disease burden.
引用
- Giollo A, Salvato M, Frizzera F, et al. Clinical application of synovial biopsy in noninflammatory and persistent inflammatory refractory rheumatoid arthritis. Ann Rheum Dis. 2025. PMID: 40846588. doi:10.1016/j.ard.2025.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。